[Changes of the level of serum antibodies to neuroantigens in patients with schizophrenia during the treatment].
The level of antibodies (AT) to neuroantigens (nerve growth factor and basic myelin protein) has been studied in the serum of 80 patients with schizophrenia, attack-like type, (ICD-10 items F20.01-02) during the treatment with psychotropic drugs. Therapeutic effectiveness has been measured clinically and with the PANSS. It has been shown that the autoimmune component is present during the acute episode of schizophrenia in about 30% of cases. No statistically significant differences have been found in the mean values of AT before and after the treatment however the dynamics of their changes has been closely related with the results of therapy: the decrease of AT level during the therapy is a predictive factor for good therapeutical remission; on the contrary, the increase of this level may be considered as an unfavorable prognostic factor.
Kliushnik
T P
TP
Siriachenko
T M
TM
Sarmanova
Z V
ZV
Otman
I N
IN
Dupin
A M
AM
Sokolov
R E
RE
D000293:Adolescent; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001323:Autoantibodies / Q000097:blood*; D001921:Brain / Q000276:immunology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D009474:Neurons / Q000276:immunology*; D012559:Schizophrenia / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology
D014150:Antipsychotic Agents; D001323:Autoantibodies